Related Experiment Video

Updated: Jun 8, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[Molecular targeted therapy for renal cell carcinoma and other urological cancers]

Hideaki Miyake1, Masato Fujisawa

  • 1Division of Urology, Kobe University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 20, 2010
PubMed

Insights

New targeted therapies, including tyrosine kinase inhibitors and mTOR inhibitors, are transforming metastatic renal cell carcinoma (RCC) treatment in Japan. This review covers their current use, quality of life impacts, and future applications in urological cancers.

Area of Science:

  • Oncology
  • Pharmacology
  • Urology

Background:

  • Metastatic renal cell carcinoma (RCC) treatment landscape in Japan has evolved significantly.
  • Recent introduction of multiple tyrosine kinase inhibitors (TKIs) like sorafenib and sunitinib has altered therapeutic strategies.
  • Upcoming availability of mammalian target of rapamycin (mTOR) inhibitors is anticipated.

Purpose of the Study:

  • To summarize the current status of molecular targeted agents for RCC treatment.
  • To discuss key issues in administering these agents, including quality of life.
  • To explore the potential use of these agents in a neoadjuvant setting.

Main Methods:

  • Review of current clinical practices and emerging therapies for metastatic RCC.
  • Analysis of the impact of targeted agents on patient quality of life.
  • Exploration of future prospects for targeted therapies in other urological cancers.

Main Results:

  • Multiple TKIs are now standard in metastatic RCC treatment in Japan.
  • mTOR inhibitors are expected to become available soon, expanding therapeutic options.
  • Quality of life considerations and neoadjuvant use are critical aspects for targeted agents.

Conclusions:

  • Molecular targeted agents represent a paradigm shift in metastatic RCC management.
  • Careful consideration of administration effects, including quality of life, is essential.
  • Future research should explore broader applications of these agents in urological oncology.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.